Oppenheimer analyst Jeff Jones lowered the firm’s price target on Pliant Therapeutics to $49 from $52 and keeps an Outperform rating on the shares. Plaint released Q3 results and demonstrated progress across the board, including bexotegrast with ongoing Phase 2 trials in both PSC and IPF and earlier stage programs ‘101095 in oncology advancing into the clinic, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PLRX:
- Pliant Therapeutics reports Q3 EPS (70c), consensus (77c)
- Pliant Therapeutics presents three posters on PLN-101095
- Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
- Pliant Therapeutics to highlight Phase 2a interim data on bexotegrast
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023